News
Lilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial
A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label expansions to reduce the risk of cardiovascular issues. | Eli Lilly has presented phase 3 results showing its Mounjaro measures up to the company’s GLP-1 Trulicity in reducing cardiovascular risks in patients with Type 2 diabetes and heart disease.
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
GlobalData on MSN19h
Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed
Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.
AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...
Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...
Lawmakers warn the arrangement Eli Lilly and Pfizer have with telehealth platforms may lead to conflicts of interest, subpar ...
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.
We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. Eli Lilly and Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback